Antibodies against advanced glycation end-products and malondialdehyde-acetaldehyde adducts identify a new specific subgroup of hitherto patients with seronegative arthritis with a distinct clinical phenotype and an HLA class II association.
Michelle D van den BeukelTineke J van WesemaelAnna Titia W HoogslagNicole V BorggrevenThomas Wj HuizingaAnnette H M van der Helm van MilRené E M ToesDiane van der WoudeLeendert Adrianus TrouwPublished in: RMD open (2023)
Anti-AGE and anti-MAA were present in around 45% of RA patients and 30% of non-RA arthritis patients, and although not specific for RA, their presence associated with HLA, inflammation and, for RA, with clinical outcomes especially in patients with seronegative RA.